Open AccessHigh sensitivity troponins and conventional troponins at the bedside
Author(s) -
Sanjeev Bhoi,
Pankaj Verma,
Sameer Ganpat Vankar,
Sagar Galwankar
Publication year - 2014
Publication title -
international journal of critical illness and injury science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.274
H-Index - 12
eISSN - 2231-5004
pISSN - 2229-5151
DOI - 10.4103/2229-5151.141471
Subject(s) - medicine , myocardial infarction , troponin , cardiology , gold standard (test) , acute coronary syndrome , troponin i , myocardial infarction diagnosis , context (archaeology) , biomarker , cardiac marker , intensive care medicine , paleontology , biology , biochemistry , chemistry
The continuing advances in the biochemical research for the discovering an ideal biomarker for diagnosing myocardial injury have led to discovery cardiac Troponin, a biochemical gold standard for myocardial necrosis. Further with advances in the immunoassay techniques, the 99th percentile cutoff value of cardiac troponin required for the diagnosis of myocardial infarction decreased, with the latest available ultrasensitive cardiac troponin assay capable of measuring level as low as 0.005 ng/ml. Troponin have both diagnostic as well as prognostic significance in myocardial necrosis, but the cut off value by 99th percentile rule is useful only when applied to patients with a high pretest probability of Acute Coronary Syndrome(ACS) and also the results must be interpreted in the context of clinical history, ECG findings, and possibly cardiac imaging to establish the correct diagnosis. As cardiac troponins are also elevated in other cardiac conditions such as cardiomyopaties, the serial monitoring of the cardiac troponin level along with the absolute value would help to differentiate myocardial infarction from these many varied conditions, with the interval of serial assay being reduced to 3 hours. The aim of this review is to complement the advantages, to emphasize on proper interpretation of positive results, to appraise the challenges faced with the available cardiac troponin assays and need for further research to overcome them and build up the most ideal cardiac marker for diagnosing the myocardial infarction.